Beginning this month, researchers from VUMC and the University of Vermont are launching a study to examine whether cognitive changes that occur at menopause for some women are related to an increased risk for Alzheimer's disease.

A drug used to treat and prevent HIV/AIDS is showing promise as a potential therapy for Alzheimer’s disease.

Poorly functioning AMPARs have been linked to a wide range of neurological and psychiatric disorders including seizures, Alzheimer’s disease, major depression and autism spectrum disorder. Understanding how AMPARs are formed and operate is essential for the rational design of pharmacological compounds that, by tuning AMPAR activity up or down, could improve treatment of these conditions.

Sleep experts published a JAMA Neurology commentary in which they recap large epidemiological studies to advocate for ending the practice.

Matthew Schrag, MD, PhD, assistant professor of Neurology, has received a Paul B. Beeson Emerging Leaders Career Development Award in Aging for research into the function of a novel protein linked to Alzheimer’s disease risk.

A new multisite study will examine whether co-occurring Alzheimer’s disease and stage 4 breast or prostate cancer alters pain perception, potentially leading to undertreated cancer pain.

Vanderbilt investigators have linked genetic mutations in a single receptor to epilepsy, autism and intellectual disability.